ʻO Changzhou Pharmaceutical Factory Ltd.,he lālā o Shanghai Pharmaceutical Holdings, ua loaʻa iā ia ka palapala hoʻopaʻa inoa lāʻau (Certificate No. 2021S01077, 2021S01078, 2021S01079) i hoʻopuka ʻia e ka State Drug Administration noLenalidomide Capsules(Specification 5mg, 10mg, 25mg), i ʻae ʻia no ka hana ʻana.
ʻIke kumu
Ka inoa lāʻau lapaʻau:Lenalidomide capsules
ʻO ke ʻano hoʻohana:Kāpena
Hōʻike:5mg, 10mg, 25mg
Ka hoʻopaʻa inoa ʻana:Papa lāʻau kemika 4
Helu hui:Palapala Laau Laau Moku'āina H20213802, Palapala Laau Laau Moku'āina H20213803, Palapala Laau Moku'āina H20213804
Hoʻopau ʻae ʻia: E hoʻokō i nā koi o ka hoʻopaʻa inoa lāʻau, ʻae ʻia no ka hoʻopaʻa inoa ʻana, hoʻopuka i kahi palapala hoʻopaʻa inoa lāʻau.
ʻIke pili
LenalidomideHe hanauna hou ia o ka lāʻau immunomodulatory waha me ka hana o ke kāohi ʻana i ka hoʻonui ʻana o ka cell tumo, hoʻoulu i ka apoptosis cell tumor a me ka immunomodulation, i hoʻohana nui ʻia i ka mālama ʻana i ka myeloma a me ka myelodysplastic syndrome (MDS) a me nā kūlana ʻē aʻe.Hoʻohana ʻia ia me ka dexamethasone e mālama i nā poʻe maʻi me nā myeloma lehulehu i mālama ʻole ʻia ma mua ʻaʻole nā ​​moho no ka hoʻololi ʻana.Hoʻohana pū ʻia kēia huahana me ka dexamethasone e mālama i nā poʻe maʻi me ka myeloma lehulehu i loaʻa i hoʻokahi lāʻau lapaʻau ma mua.Hoʻohana ʻia kēia huahana me ka rituximab e mālama i nā poʻe maʻi me ka follicular lymphoma (mau papa 1-3a) i loaʻa i ka lāʻau lapaʻau mua.
Ua hoʻokumu mua ʻia nā capsules Lenalidomide e Celgene Biopharmaceuticals a kūʻai ʻia i ka US ma 2005. i Dekemaba 2019, ua waiho ʻo Changzhou Pharmaceutical Factory i kahi palapala hoʻopaʻa inoa a kūʻai aku me ka State Drug Administration no ka lāʻau lapaʻau, i ʻae ʻia.
Hōʻike ka ʻikepili mai Minene.com i ke kūʻai aku ʻana o ka mokuʻāina o nā capsules Nalidomide i 2020 ma kahi o RMB 1.025 biliona.
Wahi a nā kulekele aupuni kūpono, ʻo nā ʻano lāʻau lapaʻau i ʻae ʻia e like me ka papa inoa inoa hou e loaʻa i ke kākoʻo nui aʻe ma nā wahi e like me ka uku ʻinikua olakino a me ke kūʻai ʻana i ke keʻena olakino.No laila, ua ʻae ʻia ka hana ʻana oHale Hana Laau Laau o Changzhou's lenalidomidecapsule mea conducive e hoonui hou aku i kona market mahele ma ke kula o ka hematology-tumor lapaau a me ka hoʻonui i kona market competitiveness, a me ka hoahu waiwai 'ike no ka hui ma hope o nā huahana e hoʻokō generic hoʻomohala lāʻau a me ka hoʻopaʻa inoa.